Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress

Reuters

2025/06/13

Enliven <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia $(CML.UK)$. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response $(MMR.AU)$ rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543688000"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543688000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543688000?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543688000","market":"us","top_or_hot":-1,"title":"Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a>. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response <a href=\"https://laohu8.com/S/MMR.AU\">$(MMR.AU)$</a> rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-13 18:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enliven <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia <a href=\"https://laohu8.com/S/CML.UK\">$(CML.UK)$</a>. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response <a href=\"https://laohu8.com/S/MMR.AU\">$(MMR.AU)$</a> rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELVN","symbol_name":"Enliven Treateutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL9dn6BH:1","article_id":"2543688000","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543688000","pubTimestamp":1749809004,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia . The data was presented at the European Hematology Association  2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response  rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELVN":"Enliven Treateutics","BK4007":"制药"},"translate_title":"Enliven Therapeutics在EHA 2025大会上宣布ELVN-001治疗CML的积极1期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELVN":0.9},"content_text":"Enliven Therapeutics Announces Positive Phase 1 Trial Results for ELVN-001 in CML at EHA 2025 Congress\n    \n\n        Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in small molecule therapeutics, announced updated positive results from their Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia $(CML.UK)$. The data was presented at the European Hematology Association (EHA) 2025 Congress, taking place from June 12-15 in Milan, Italy, and virtually. The trial reported a cumulative major molecular response $(MMR.AU)$ rate of 47% by 24 weeks, with a favorable safety and tolerability profile across all dose levels. Enliven plans to initiate a Phase 3 pivotal trial in 2026, aiming to position ELVN-001 as a competitive treatment option in the CML landscape. Enliven will discuss these findings during a webcast and conference call on June 13, 2025, at 1:30 p.m. ET.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA09748) on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}